These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 9455457)

  • 41. Prevention of emesis by ICS 205-930 in children receiving cytotoxic chemotherapy.
    Hachimi-Idrissi S; De Schepper J; Maurus R; Otten J
    Eur J Cancer; 1993; 29A(6):854-6. PubMed ID: 8484976
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The beneficial action of Navoban during antineoplastic chemotherapy].
    Garin AM; Kupchan DZ; Kirsanov AG; Ivanova NM; Il'iashenko VV
    Ter Arkh; 1993; 65(10):59-60. PubMed ID: 7507603
    [No Abstract]   [Full Text] [Related]  

  • 43. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
    Abali H; Celik I
    Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early clinical trial of MDL 73.147 EF: a new 5-HT3-receptors antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Kirchner V; Aapro M; Alberto P; O'Grady P; Busch B; Boyce M
    Ann Oncol; 1993 Jun; 4(6):481-4. PubMed ID: 8353090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effects of an anti-emetic tropisetron capsule on QOL of patients with delayed nausea and vomiting induced by cancer chemotherapy. Group for Investigation of QOL Questionnaire for Anti-Emetics used in Cancer Chemotherapy. Joint Research Group for Tropisetron Double-Blind Comparative Study].
    Nukariya N; Kobayashi K; Ishihara Y; Yoneda S; Matsuda T; Yakushiji M; Yamakido M; Fukuoka M; Niitani H; Furue H
    Gan To Kagaku Ryoho; 1996 May; 23(6):757-71. PubMed ID: 8645027
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The development of a protocol for the use of 5-HT3 antagonists in chemotherapy-induced nausea and vomiting.
    Watters J; Riley M; Pedley I; Whitehead A; Overend M; Goss I; Allgar V
    Clin Oncol (R Coll Radiol); 2001; 13(6):422-6. PubMed ID: 11824878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tropisetron in the prevention of chemotherapy-induced nausea and vomiting: the Nordic experience.
    Sorbe B
    Ann Oncol; 1993; 4 Suppl 3():39-42. PubMed ID: 8363999
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The prevention and treatment of nausea and vomiting during cancer chemotherapy].
    Shparyk IaV; Bilyns'kyĭ BT; Koval'chuk IV; Petriv RM; Kachmar TB; Ohorchak MA
    Lik Sprava; 1997; (4):148-52. PubMed ID: 9471361
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I antiemetic study of MDL 73,147EF, a novel 5-hydroxytryptamine antagonist in cancer patients receiving emetogenic chemotherapy.
    Merrouche Y; Catimel G; Rebattu P; Dumortier A; Guastalla JP; O'Grady P; Clavel M
    Ann Oncol; 1994 Jul; 5(6):549-51. PubMed ID: 7918128
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Experience with the clinical use of navoban].
    Voznyĭ EK; Dobrovol'skaia NI; Volkova LA
    Vopr Onkol; 1995; 41(1):70-1. PubMed ID: 7667947
    [No Abstract]   [Full Text] [Related]  

  • 51. Prevention of chemotherapy-induced nausea and emesis in patients responding poorly to previous antiemetic therapy. Comparing tropisetron with optimised standard antiemetic therapy.
    Bruntsch U; Drechsler S; Hiller E; Eiermann W; Tulusan AH; Bühner M; Hartenstein R; Koenig HJ; Gallmeier WM
    Drugs; 1992; 43 Suppl 3():23-6. PubMed ID: 1380429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting.
    Van Belle SJ; Stamatakis L; Bleiberg H; Cocquyt VF; Michel J; de Bruijn KM
    Ann Oncol; 1994 Nov; 5(9):821-5. PubMed ID: 7848884
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Antiemetic treatment and chemotherapy: general review].
    Lecomte S; Adenis A; Bonneterre J
    Rev Med Interne; 1994; 15(11):752-69. PubMed ID: 7846392
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Three years' experience with tropisetron in the control of nausea and vomiting in cisplatin-treated patients.
    Dogliotti L; Antonacci RA; Pazè E; Ortega C; Berruti A; Faggiuolo R
    Drugs; 1992; 43 Suppl 3():6-10. PubMed ID: 1380432
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Navoban--the new 5HT3-antagonist].
    Internist (Berl); 1994 May; 35(5 Suppl):1-8. PubMed ID: 9209536
    [No Abstract]   [Full Text] [Related]  

  • 56. [Use of Navoban in pediatric oncology].
    Safonova SA; Kolygin BA; Punanov IA; Borodina AF
    Vopr Onkol; 1996; 42(6):72-3. PubMed ID: 9123909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [The use of navoban in the therapy of oncology patients with highly emetic treatments].
    Russel AJ
    Vopr Onkol; 1995; 41(1):87-90. PubMed ID: 7667952
    [No Abstract]   [Full Text] [Related]  

  • 58. Optimal selection of antiemetics in children receiving cancer chemotherapy.
    Roila F; Aapro M; Stewart A
    Support Care Cancer; 1998 May; 6(3):215-20. PubMed ID: 9629872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tropisetron (ICS 205-930) in pediatric oncology: first results in patients refractory to antiemetic metoclopramide-based treatments.
    Cefalo G; Rottoli L; Armiraglio A; Pagan MG
    Am J Pediatr Hematol Oncol; 1994 Aug; 16(3):242-5. PubMed ID: 8037343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tropisetron (Navoban) compared with alizapride in the control of emesis induced by cyclophosphamide-containing regimens.
    De Nigris A; Paladini G; Giosa F; Sfeir C; Pagan MG; Maltoni C
    Eur J Cancer; 1994; 30A(12):1902-3. PubMed ID: 7880624
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.